Exploring Three Swedish Exchange Growth Companies With High Insider Ownership

As global markets navigate through mixed economic signals, Sweden's market remains a focal point for investors looking for growth opportunities. This context sets the stage to explore three Swedish growth companies with high insider ownership, which often indicates confidence from those closest to the company's operations and future prospects.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name	Insider Ownership	Earnings Growth
CTT Systems (OM:CTT)	16.9%	21.6%
BioArctic (OM:BIOA B)	35.1%	50.5%
Sileon (OM:SILEON)	33.3%	109.3%
KebNi (OM:KEBNI B)	37.8%	90.4%
InCoax Networks (OM:INCOAX)	17.9%	104.9%
Calliditas Therapeutics (OM:CALTX)	10.5%	52.9%
Egetis Therapeutics (OM:EGTX)	17.6%	98.2%
edyoutec (NGM:EDYOU)	14.6%	63.1%
Yubico (OM:YUBICO)	37.5%	43.4%
SaveLend Group (OM:YIELD)	24.9%	103.4%

Click here to see the full list of 81 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Attendo (OM:ATT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Attendo AB (publ) operates in the provision of health and care services across Scandinavia and Finland, with a market capitalization of approximately SEK 6.94 billion.

Operations: The company generates SEK 17.63 billion from its Care and Health Care Services segment.

Insider Ownership: 15%

Attendo is poised for notable growth with earnings forecasted to increase by 21.8% annually, outpacing the Swedish market's 14.3%. Despite a low return on equity projection of 9.3% in three years, its price-to-earnings ratio at 17.1x remains attractive compared to the Swedish average of 23.3x. Recent insider activities show more buying than selling, although not in substantial volumes, indicating moderate confidence among insiders. The company also actively engages in share repurchases to optimize capital usage and potentially enhance shareholder value.

• Unlock comprehensive insights into our analysis of Attendo stock in this growth report.
• The analysis detailed in our Attendo valuation report hints at an deflated share price compared to its estimated value.

Egetis Therapeutics (OM:EGTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Egetis Therapeutics AB is a Swedish pharmaceutical company specializing in late-stage development projects aimed at treating serious diseases within the orphan drug segment, with a market capitalization of approximately SEK 2.65 billion.

Operations: The company generates revenue primarily from its Emcitate segment, which brought in SEK 62.90 million.

Insider Ownership: 17.6%

Egetis Therapeutics is expected to shift from unprofitable to profitable within three years, with anticipated earnings growth of 98.18% per year and revenue growth significantly outpacing the Swedish market at 73.6% annually. Despite trading at a substantial discount to its estimated fair value, shareholder dilution occurred over the past year. Recently, Egetis received a Promising Innovative Medicine designation in the UK for Emcitate®, enhancing its growth prospects amidst ongoing financial challenges indicated by a short cash runway.

• Dive into the specifics of Egetis Therapeutics here with our thorough growth forecast report.
• The valuation report we've compiled suggests that Egetis Therapeutics' current price could be inflated.

Sectra (OM:SECT B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Sectra AB (publ) operates in the medical IT and cybersecurity sectors across Sweden, the United Kingdom, the Netherlands, and other parts of Europe, with a market capitalization of approximately SEK 46.55 billion.

Operations: The company's revenue is primarily generated from its Imaging IT Solutions and Secure Communications segments, which respectively contributed SEK 2.55 billion and SEK 367.40 million.

Insider Ownership: 30.3%

Sectra, a Swedish company with high insider ownership, reported robust earnings growth in its recent fiscal year with a notable increase in annual sales to SEK 3.04 billion and net income rising to SEK 428.39 million. The firm launched an innovative diagnostic IT module for genomics, potentially revolutionizing cancer treatment through precision medicine. This product expansion complements Sectra's existing enterprise imaging solutions and aligns with its strategic focus on healthcare technology advancements, though its revenue growth at 14.7% annually trails behind some market expectations.

• Get an in-depth perspective on Sectra's performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that Sectra is trading beyond its estimated value.

Where To Now?

• Unlock our comprehensive list of 81 Fast Growing Swedish Companies With High Insider Ownership by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com